RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
+64.05%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$2.61B
AUM Growth
+$2.61B
(+13%)
Cap. Flow
+$43.5M
Cap. Flow
% of AUM
1.67%
Top 10 Holdings %
Top 10 Hldgs %
53.33%
Holding
82
New
6
Increased
24
Reduced
27
Closed
10
Top Buys
| 1 |
IMGN
Immunogen Inc
IMGN
|
$183M |
| 2 |
Krystal Biotech
KRYS
|
$76.7M |
| 3 |
Cogent Biosciences
COGT
|
$24.3M |
| 4 |
CTLT
CATALENT, INC.
CTLT
|
$23.9M |
| 5 |
Zimmer Biomet
ZBH
|
$22M |
Top Sells
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$102M |
| 2 |
argenx
ARGX
|
$48.6M |
| 3 |
OSH
Oak Street Health, Inc.
OSH
|
$41.1M |
| 4 |
Sarepta Therapeutics
SRPT
|
$31.9M |
| 5 |
Bristol-Myers Squibb
BMY
|
$31.2M |
Sector Composition
| 1 | Healthcare | 97.02% |
| 2 | Industrials | 2.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
IMGN
1
DELISTED
Immunogen Inc
IMGN
| $335M | 12.84% | 17,730,417 +9,684,200 | +120% | +$183M |
|
|
2
Krystal Biotech
KRYS
$4.27B
| $301M | 11.57% | 2,566,661 +653,381 | +34% | +$76.7M |
|
3
Amicus Therapeutics
FOLD
$2.34B
| $246M | 9.43% | 19,566,961 +1,220,100 | +7% | +$15.3M |
|
4
Replimune Group
REPL
$422M
| $103M | 3.94% | 4,420,533 +608,545 | +16% | +$14.1M |
|
5
Akero Therapeutics
AKRO
$3.74B
| $84.6M | 3.25% | 1,811,672 -232,717 | -11% | -$10.9M |
|
|
AUGX
6
DELISTED
Augmedix, Inc. Common Stock
AUGX
| $75.2M | 2.89% | 15,630,327 +1,250,000 | +9% | +$6.01M |
|
|
DCPH
7
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $68.7M | 2.64% | 4,878,566 -703,539 | -13% | -$9.91M |
|
8
Fate Therapeutics
FATE
$120M
| $62.5M | 2.4% | 13,124,427 +167,205 | +1% | +$796K |
|
9
Celldex Therapeutics
CLDX
$1.47B
| $57.5M | 2.21% | 1,696,004 -183,735 | -10% | -$6.23M |
|
10
LivaNova
LIVN
$3.08B
| $56.6M | 2.17% | 1,100,492 -85,926 | -7% | -$4.42M |
|
|
CTLT
11
DELISTED
CATALENT, INC.
CTLT
| $50.4M | 1.93% | 1,162,166 +551,862 | +90% | +$23.9M |
|
12
Zymeworks
ZYME
$1.12B
| $48.9M | 1.88% | 5,661,230 -406,688 | -7% | -$3.51M |
|
13
Pliant Therapeutics
PLRX
$101M
| $48.5M | 1.86% | 2,678,099 -247,549 | -8% | -$4.49M |
|
14
Penumbra
PEN
$10.6B
| $47.8M | 1.84% | 138,970 -49,022 | -26% | -$16.9M |
|
15
Beam Therapeutics
BEAM
$1.66B
| $47.4M | 1.82% | 1,485,199 -126,895 | -8% | -$4.05M |
|
16
Xenon Pharmaceuticals
XENE
$2.98B
| $43.1M | 1.66% | 1,120,476 -205,356 | -15% | -$7.91M |
|
17
Kymera Therapeutics
KYMR
$2.95B
| $43M | 1.65% | 1,868,507 -542,262 | -22% | -$12.5M |
|
18
BioMarin Pharmaceuticals
BMRN
$11.2B
| $42.4M | 1.63% | 489,208 +154,038 | +46% | +$13.4M |
|
19
Jazz Pharmaceuticals
JAZZ
$7.75B
| $42.4M | 1.63% | 341,882 +6,723 | +2% | +$833K |
|
20
Stoke Therapeutics
STOK
$1.08B
| $42M | 1.61% | 3,955,188 -190,208 | -5% | -$2.02M |
|
21
Regenxbio
RGNX
$451M
| $40.5M | 1.55% | 2,026,576 +385,851 | +24% | +$7.71M |
|
22
DexCom
DXCM
$29.5B
| $37.2M | 1.43% | 289,161 -46,887 | -14% | -$6.03M |
|
23
Immunovant
IMVT
$2.56B
| $36.4M | 1.4% | 1,921,152 +604,121 | +46% | +$11.5M |
|
24
Elevance Health
ELV
$71.8B
| $34.8M | 1.34% | 78,313 +11,915 | +18% | +$5.29M |
|
25
Scholar Rock
SRRK
$3.14B
| $33.2M | 1.27% | 4,403,840 +1,279,614 | +41% | +$9.65M |
|